Kyowa Hakko Bio, Co., Ltd v. Ajinomoto Co., Ltd.

CourtDistrict Court, D. Delaware
DecidedOctober 9, 2019
Docket1:17-cv-00313
StatusUnknown

This text of Kyowa Hakko Bio, Co., Ltd v. Ajinomoto Co., Ltd. (Kyowa Hakko Bio, Co., Ltd v. Ajinomoto Co., Ltd.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kyowa Hakko Bio, Co., Ltd v. Ajinomoto Co., Ltd., (D. Del. 2019).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

Kyowa Hakko Bio, Co., Ltd, et al : CIVIL ACTION Plaintiffs, : : v. : : NO. 17-cv-00313-MSG Ajinomoto Co., Ltd. et al : Defendants. :

CLAIM CONSTRUCTION OPINION RICHARD A. LLORET October 9, 2019 U.S. MAGISTRATE JUDGE INTRODUCTION Kyowa Hakko Bio, Co., Ltd. and related companies (“Plaintiffs,” or “Kyowa”) filed a complaint claiming that Ajinomoto Co. Ltd. and related companies (“Defendants,” or “Ajinomoto”) infringe their U.S. Patent No. 45,723 (“the ‘723 patent” or “’723”) by making amino acids1 by a method2 claimed in the ‘723 patent. Docket Item (“D.I.”) 1, ¶ 1-2. The case has been referred to me for claim construction under Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996). D.I. 76. The parties have briefed the issues thoroughly, and I held oral argument on July 29, 2019. This opinion construes the disputed claim language. STANDARD OF REVIEW “[T]he claims of a patent define the invention to which the patentee is entitled the right to exclude.” Eli Lilly and Company v. Eagle Pharmaceuticals, Inc., 2019 WL 1299212, at *1 (D.Del. 2019) (quoting Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc., 381 F.3d 1111, 1115 (Fed. Cir. 2004)). Claim construction is a

1 Or by importing or selling them in the United States. 2 Or an equivalent method. question of law. Teva Pharm. USA, Inc. v. Sandoz, Inc., 135 S.Ct. 831, 837 (2015). Claim terms generally are given “the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention.” Phillips v. AWH Corp., 415 F.3d 1303, 1313 (Fed. Cir. 2005) (quoted in Eli Lilly, 2019 WL 1299212, at *1). This general rule gives way when the patentee sets out a defined term in the patent, or disavows the

full scope of the term’s ordinary meaning, either in the specification or during prosecution. Unwired Planet, LLC v. Apple Inc., 829 F.3d 1353, 1358 (Fed. Cir. 2016). Courts look for a term’s ordinary meaning in the “intrinsic evidence,” which is the claim language, the specification, and the prosecution history. Leseman, LLC v. Stratasys, Inc., 730 F. App’x 912, 914 (Fed. Cir. 2018). If necessary, a court may also look to “extrinsic evidence,” which includes “expert and inventor testimony, dictionaries, and learned treatises.” Markman v. Westview Instruments, Inc., 52 F.3d 967, 980 (Fed. Cir. 1995). Extrinsic evidence may not be used “for the purpose of varying or contradicting the terms of the claims.” Markman, 52 F.3d at 981. “The construction that stays true to the claim language and most naturally aligns with the patent’s description of the invention will be, in the end, the correct construction.”

Renishaw PLC v. Marposs Societa’ per Azioni, 158 F.3d 1243, 1250 (Fed. Cir. 1998). BACKGROUND Amino acids are mass produced by fermentation. Declaration of Dr. Michael F. Doherty (“Doherty”), D.I. 84, at ¶¶16–18; Declaration of Dr. Allen S. Myerson (“Myerson”), D.I. 85, at ¶¶1-15. Fermentation is a process that uses microorganisms (often bacteria) to produce a chemical. Id. The bacteria are placed in a fermentation broth, also called a culture, in which the bacteria grow, releasing amino acids into the broth as a by-product. Id. The amino acids eventually crystalize and can then be separated from the bacteria in the broth. ’723 patent at 1:18–41. The broth becomes more and more concentrated as the bacteria produces amino acids, until the broth reaches a point called saturation, which means that under the existing conditions the broth cannot hold any more dissolved amino acid. Doherty at

¶¶18 –19; Myerson at ¶15. If more amino acid is added to a saturated solution it becomes “supersaturated.” Id. In a supersaturated solution, the amino acids precipitate (“nucleate out”) and begin to form crystals. Doherty at ¶¶18 –19; Myerson at ¶¶15-16. “Seeding” crystal particles into the broth can change the growth pattern of amino acid crystals. The amino acids latch onto the seed crystals and grow larger crystal particles than they would if nucleated out on their own. Myerson at ¶16. These larger crystals can then be more easily harvested from the broth. Doherty at ¶¶20–21. Seed crystals of the desired size can be introduced into the broth directly, or by different types of agitation, shock, friction, and pressure. Doherty at ¶23-25. THE PATENT Claim 1 of the ‘723 patent (referred to as “Claim 1”) describes a process for

efficiently growing amino acid crystals in an amino acid broth by adding (“seeding”) amino acid crystals of a particular average size to the broth at a particular time in the brewing process. D.I. 1, ¶56. Claim 1 measures the results of the process by the concentration of the crystals produced. Id. Claim 2 of the ‘723 patent adopts the process in Claim 1, but measures the results differently. Id., ¶57. Claims 7 and 8 are dependent on Claims 1 and 2, respectively. Id., at ¶59. Both Claims 1 and 2 require that added crystals be within a specific size range, defined by their “average particle size,” and be added at a particular time. Pl. Br. at 1. Claim 1 of the patent reads as follows:3

1. A process for producing an amino acid, which comprises:

[a] culturing a microorganism having an ability to produce the amino acid in a medium,

[b] adding crystals of the amino acid having an average particle size of 7 to 50 μm to the medium at some time after the amino acid concentration in the medium reaches the saturation solubility and before crystals of the amino acid deposit in the medium so that the concentration of the crystals of the amino acid becomes 0.5 g/l or more,

[c] culturing the microorganism having the ability to produce the amino acid in the medium,

[d] allowing the crystals of the amino acid to grow to crystals of the amino acid having an average particle size of 30 μm or more and accumulate in the medium, and

[e] recovering the crystals of the amino acid from the culture by separating the microorganism producing the amino acid and the accumulated crystals of the amino acid based on the difference in particle size or specific gravity between them.

D.I. 1, ¶56. Claim 2 tracks the language of Claim 1, but where Claim 1 requires the concentration of the crystals to reach a certain number of grams per liter (sub- paragraph (b)), Claim 2 requires the crystals in the medium to reach a certain total surface area. ‘723 patent at 11:8-10. The ’723 patent purported to solve some problems with then existing methods of collecting amino acids from a broth. One problem was that high concentration of amino acids in the broth tended to inhibit further production of crystals. ‘723 patent at 1:31- 32.4 Prior methods also yielded a lot of microcrystals that were difficult to separate from the broth because of their extremely small size. ‘723 patent at 1:42–51. Because the

3 I have inserted subparagraph markings [a] – [e], for convenience, following the Complaint. D.I. 1, ¶ 56. The full text of the patent is reproduced as an Exhibit to the Complaint. 4 Patent references are to the column numbers within the patent (listed before the colon) and lines (listed after the colon).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Epistar Corp. v. International Trade Commission
566 F.3d 1321 (Federal Circuit, 2009)
Aia Engineering Ltd. v. Magotteaux Intern. S/A
657 F.3d 1264 (Federal Circuit, 2011)
The Gillette Company v. Energizer Holdings, Inc.
405 F.3d 1367 (Federal Circuit, 2005)
Starhome Gmbh v. AT & T Mobility LLC
743 F.3d 849 (Federal Circuit, 2014)
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
789 F.3d 1335 (Federal Circuit, 2015)
The Dow Chemical Company v. Nova Chemicals Corporation
803 F.3d 620 (Federal Circuit, 2015)
Unwired Planet, LLC v. Apple Inc.
829 F.3d 1353 (Federal Circuit, 2016)
Continental Circuits LLC v. Intel Corporation
915 F.3d 788 (Federal Circuit, 2019)
Teva Pharm. United States, Inc. v. Sandoz, Inc.
135 S. Ct. 831 (Supreme Court, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
Kyowa Hakko Bio, Co., Ltd v. Ajinomoto Co., Ltd., Counsel Stack Legal Research, https://law.counselstack.com/opinion/kyowa-hakko-bio-co-ltd-v-ajinomoto-co-ltd-ded-2019.